First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy
- PMID: 31002957
- DOI: 10.1016/j.jaip.2019.04.010
First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy
Abstract
Background: In 2017, a clinical trial of 37 subjects demonstrated that preschool peanut oral immunotherapy (P-OIT) was safe, with predominantly mild symptoms reported and only 1 moderate reaction requiring epinephrine.
Objectives: We sought to examine whether these findings would be applicable in a real-world setting.
Methods: As part of a Canada-wide quality improvement project, community and academic allergists administered P-OIT to preschool-age children who had (1) skin prick test wheal diameter greater than or equal to 3 mm or specific IgE level greater than or equal to 0.35 kU/L and history of reaction and/or positive baseline oral food challenge, or (2) no ingestion history and specific IgE level greater than or equal to 5 kU/L. Over 16 to 22 weeks, patients had biweekly clinic visits for updosing, and consumed the dose daily at home between visits. Target maintenance dose was 300 mg peanut protein. Symptoms were classified using a modified World Allergy Organization Subcutaneous Immunotherapy Reaction Grading System (1 mildest, 5 fatal).
Results: Of 270 patients who started P-OIT in the period 2017 to 2018, 243 reached maintenance, and 27 dropped out (10.0%); 67.8% of patients experienced reactions during buildup: 36.3% grade 1, 31.1% grade 2, and 0.40% grade 4. Eleven patients (4.10%) received epinephrine (10 patients received 1 dose, 1 patient received epinephrine on 2 separate days), representing 2.23% of reactions (12 of 538) and 0.029% of doses (12 of 41,020).
Conclusions: We are the first group to describe preschool P-OIT in a real-world multicenter setting. The treatment appears to be safe for the vast majority of patients because symptoms were generally mild and very few reactions received epinephrine; however, life-threatening reactions in a minority of patients (0.4%) can still occur.
Keywords: Adverse events; Allergic reactions; Oral immunotherapy; Peanut allergy; Peanut oral immunotherapy; Preschool children; Preschoolers; Real-world; Safety.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Comment in
-
Peanut Oral Immunotherapy: Is It Safer in Preschoolers than in Older Age Groups?J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2768-2769. doi: 10.1016/j.jaip.2019.07.027. J Allergy Clin Immunol Pract. 2019. PMID: 31706493 No abstract available.
Similar articles
-
Real-World Safety Analysis of Preschool Tree Nut Oral Immunotherapy.J Allergy Clin Immunol Pract. 2023 Apr;11(4):1177-1183. doi: 10.1016/j.jaip.2023.01.031. Epub 2023 Feb 1. J Allergy Clin Immunol Pract. 2023. PMID: 36736958
-
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4. Lancet Child Adolesc Health. 2022. PMID: 35123664 Clinical Trial.
-
The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.Int Arch Allergy Immunol. 2012;159(2):179-82. doi: 10.1159/000336391. Epub 2012 Jun 1. Int Arch Allergy Immunol. 2012. PMID: 22678151 Free PMC article. Clinical Trial.
-
Current Trend in Immunotherapy for Peanut Allergy.Int Rev Immunol. 2018;37(6):279-290. doi: 10.1080/08830185.2018.1509967. Epub 2019 Jan 13. Int Rev Immunol. 2018. PMID: 30638084 Review.
-
Peanut Oral Immunotherapy: a Current Perspective.Curr Allergy Asthma Rep. 2020 Apr 20;20(5):14. doi: 10.1007/s11882-020-00908-6. Curr Allergy Asthma Rep. 2020. PMID: 32314071 Free PMC article. Review.
Cited by
-
Oral Immunotherapy in Children: Clinical Considerations and Practical Management.J Asthma Allergy. 2021 Dec 14;14:1497-1510. doi: 10.2147/JAA.S282696. eCollection 2021. J Asthma Allergy. 2021. PMID: 34934327 Free PMC article. Review.
-
Safety and adherence of early oral immunotherapy for peanut allergy in a primary care setting: a retrospective cross-sectional study.Allergy Asthma Clin Immunol. 2024 Oct 24;20(1):57. doi: 10.1186/s13223-024-00916-5. Allergy Asthma Clin Immunol. 2024. PMID: 39449085 Free PMC article.
-
Assessment of multiple-opinion referrals and consults at the BC Children's Hospital Allergy Clinic.Allergy Asthma Clin Immunol. 2023 Jun 14;19(1):52. doi: 10.1186/s13223-023-00806-2. Allergy Asthma Clin Immunol. 2023. PMID: 37316941 Free PMC article.
-
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.Lancet. 2022 Jan 22;399(10322):359-371. doi: 10.1016/S0140-6736(21)02390-4. Lancet. 2022. PMID: 35065784 Free PMC article. Clinical Trial.
-
Selecting patients for food allergy therapy.J Food Allergy. 2024 Aug 1;7(1):3-6. doi: 10.2500/jfa.2025.7.250003. eCollection 2024 Aug. J Food Allergy. 2024. PMID: 40771708 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials